Kalytera Names Ronald P. Erickson To Board
This article was originally published in Scrip
Kalytera Therapeutics Inc., a company developing a portfolio of non-psychoactive cannanbinoid (CBD) and synthetic CBD medicines, has appointed Ronald P. Erickson to its board of directors. Senior business executive Erickson brings more than 30 years' experience to Kalytera and currently he is the founder, CEO, president and chair of Visualant Inc. He is also on various corporate boards including Bioasis Technologies, a company focused on the delivery of therapeutics across the blood-brain barrier.